Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
European Urology Oncology|November 9, 2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216Umang Swami, Yeonjung Jo, Arshit Narang, et al.
The New England Journal of Medicine|October 8, 2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerDaniel P Petrylak, Catherine M Tangen, Maha H A Hussain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 studyTanya B Dorff, Thomas W Flaig, Catherine M Tangen, et al.
Journal of the National Cancer Institute|April 20, 2006
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16Daniel P Petrylak, Donna Pauler Ankerst, Caroline S Jiang, et al.
European Urology|April 21, 2024
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS StudyFred Saad, Maha H A Hussain, Bertrand Tombal, et al.
JAMA Network Open|October 7, 2024
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate CancerAmir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Clinical Genitourinary Cancer|June 6, 2017
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421Guru Sonpavde, Gregory R Pond, Melissa Plets, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 21, 2022
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)Neeraj Agarwal, Catherine M Tangen, Maha H A Hussain, et al.
European Urology Oncology|March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or BicalutamideMamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2021
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)Amir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Pageof 5